Literature DB >> 23448774

Oxaliplatin-induced acute thrombocytopenia: a case report and review of the literature.

Kei Suzuki1, Hiroyasu Oda, Yumiko Sugawara, Masahiro Masuya, Kazunori Nakase, Masaki Fujioka, Hiroshi Imai, Naoyuki Katayama.   

Abstract

We herein report the case of a 77-year-old woman who developed acute thrombocytopenia during the 23rd cycle of modified FOLFOX therapy. She developed a hypersensitivity reaction with nasal bleeding. The chemotherapy infusion was immediately discontinued. The patient's symptoms resolved with discontinuation of chemotherapy and the administration of supportive therapy. A complete blood count showed severe thrombocytopenia, and oxaliplatin-induced thrombocytopenia was diagnosed. The patient was admitted to the hospital, and the thrombocytopenia was corrected with a platelet transfusion followed by prednisolone. She was discharged after one week without requiring additional platelet transfusions. With the widespread use of oxaliplatin, the risk of oxaliplatin-induced acute thrombocytopenia should be considered an acute onset hematological emergency.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448774     DOI: 10.2169/internalmedicine.52.8933

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report.

Authors:  Hyun Sun Woo; Kyoung Hwa Lee; Phill Hoon Yoon; Su Ji Kim; Inkeun Park; Young Saing Kim; Hee Kyung Ahn; Junshik Hong; Dong Bok Shin; Sun Jin Sym
Journal:  Cancer Res Treat       Date:  2014-10-28       Impact factor: 4.679

2.  Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study.

Authors:  Sven Van Poucke; Dana Huskens; Kurt Van der Speeten; Mark Roest; Bart Lauwereins; Ming-Hua Zheng; Seppe Dehaene; Joris Penders; Abraham Marcus; Marcus Lancé
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

3.  Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy.

Authors:  Eric L Tam; Padma L Draksharam; Jennifer A Park; Gurinder S Sidhu
Journal:  Case Rep Oncol Med       Date:  2019-11-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.